Johnson & Johnson’s ICOTYDE®: Breakthrough Data for Plaque Psoriasis Treatment Demonstrates Long-Term Efficacy#USA#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Johnson & Johnson’s ICOTYDE®: Breakthrough Data for Plaque Psoriasis Treatment Demonstrates Long-Term Efficacy
Johnson & Johnson announces significant two-year results for ICOTYDE® in treating difficult plaque psoriasis, confirming its effectiveness and durability in patients.
third-news.com
October 2, 2026 at 10:14 AM
Johnson & Johnson’s ICOTYDE®: Breakthrough Data for Plaque Psoriasis Treatment Demonstrates Long-Term Efficacy#USA#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed
Johnson & Johnson reported promising year-long results for ICOTYDE™, a once-daily oral treatment for plaque psoriasis, confirming its effectiveness and safety.
third-news.com
March 28, 2026 at 2:14 PM
Long-Term Efficacy and Safety of ICOTYDE™ in Plaque Psoriasis Patients Revealed#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis
Johnson & Johnson's ICOTYDE™ has received FDA approval as a novel oral treatment for moderate-to-severe plaque psoriasis, a significant advancement for patient care.
third-news.com
March 18, 2026 at 11:57 AM
ICOTYDE™: A Breakthrough Oral Treatment Approved for Plaque Psoriasis#United_States#Johnson_&_Johnson#Spring_House#Plaque_Psoriasis#ICOTYDE
Accro Bioscience to Unveil Phase II Data at European Dermatology Congress 2025#None#Paris#Plaque_Psoriasis#AC-201#Accro_Bioscience
Accro Bioscience to Unveil Phase II Data at European Dermatology Congress 2025
Accro Bioscience is set to present crucial Phase II clinical data on AC-201 for treating plaque psoriasis at EADV Congress 2025 in Paris. Discover the latest advancements.
third-news.com
September 4, 2025 at 1:48 PM
Accro Bioscience to Unveil Phase II Data at European Dermatology Congress 2025#None#Paris#Plaque_Psoriasis#AC-201#Accro_Bioscience
Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment#China#Suzhou#Accropeutics#Plaque_Psoriasis#AC-201
Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment
Accropeutics has announced promising Phase 2 trial results for AC-201, an oral TYK2/JAK1 inhibitor, aimed at treating plaque psoriasis, paving the way for further development.
third-news.com
May 21, 2025 at 12:57 AM
Accropeutics Unveils Positive Phase 2 Trial Results for AC-201 in Psoriasis Treatment#China#Suzhou#Accropeutics#Plaque_Psoriasis#AC-201
Promising Results of Icotrokinra in Treating Adolescents with Plaque Psoriasis#United_States#Johnson_&_Johnson#Spring_House#Icotrokinra#Plaque_Psoriasis
Promising Results of Icotrokinra in Treating Adolescents with Plaque Psoriasis
Johnson & Johnson's recent study shows Icotrokinra's effectiveness in treating plaque psoriasis in teenagers, achieving clear skin for 75% of participants.
third-news.com
April 10, 2025 at 12:12 PM
Promising Results of Icotrokinra in Treating Adolescents with Plaque Psoriasis#United_States#Johnson_&_Johnson#Spring_House#Icotrokinra#Plaque_Psoriasis
Icotrokinra Emerges as a Game-Changer in Plaque Psoriasis Treatment#United_States#Johnson_&_Johnson#Spring_House#Icotrokinra#Plaque_Psoriasis
Icotrokinra Emerges as a Game-Changer in Plaque Psoriasis Treatment
New findings on icotrokinra reveal its potential to redefine treatment for plaque psoriasis, showcasing impressive skin clearance and safety in a daily oral form.
third-news.com
March 8, 2025 at 2:08 PM
Icotrokinra Emerges as a Game-Changer in Plaque Psoriasis Treatment#United_States#Johnson_&_Johnson#Spring_House#Icotrokinra#Plaque_Psoriasis